Figure 1.

Clinical status quo of the potential treatment options for KRAS^mut pancreatic ductal adenocarcinoma (PDAC) (adapted from Moore et al.) [58]. Apart from the direct targeting of KRAS^mut with covalent allele-specific inhibitors as well as farnesylation inhibitors (A), indirect inhibition has gained more and more momentum (B). Here, approved drugs are depicted in green, ongoing clinical trials in yellow, and in red compounds that have failed to show benefit in clinical studies. Promising preclinical candidates are marked in grey. Empty circles represent the status of compounds that have not been approved or tested in PDAC. Filled circles indicate that these compounds have explicitly been approved for PDAC or tested at least in (advanced) solid tumors including PDAC.